The stock of Xeris Biopharma Holdings Inc (XERS) has gone up by 13.50% for the week, with a 23.12% rise in the past month and a 40.47% rise in the past quarter. The volatility ratio for the week is 5.75%, and the volatility levels for the past 30 days are 6.86% for XERS. The simple moving average for the last 20 days is 17.21% for XERS’s stock, with a simple moving average of 45.85% for the last 200 days.
Is It Worth Investing in Xeris Biopharma Holdings Inc (NASDAQ: XERS) Right Now?
XERS has 36-month beta value of 0.69. Analysts have mixed views on the stock, with 4 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for XERS is 141.94M, and currently, short sellers hold a 13.42% ratio of that float. The average trading volume of XERS on May 08, 2025 was 3.12M shares.
XERS) stock’s latest price update
The stock price of Xeris Biopharma Holdings Inc (NASDAQ: XERS) has jumped by 13.50 compared to previous close of 4.48. Despite this, the company has seen a gain of 13.50% in its stock price over the last five trading days. zacks.com reported 2025-05-08 that Xeris Biopharma (XERS) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.14 per share a year ago.
Analysts’ Opinion of XERS
Many brokerage firms have already submitted their reports for XERS stocks, with Piper Sandler repeating the rating for XERS by listing it as a “Neutral.” The predicted price for XERS in the upcoming period, according to Piper Sandler is $3 based on the research report published on November 11, 2024 of the previous year 2024.
Oppenheimer, on the other hand, stated in their research note that they expect to see XERS reach a price target of $5. The rating they have provided for XERS stocks is “Outperform” according to the report published on March 28th, 2024.
Craig Hallum gave a rating of “Buy” to XERS, setting the target price at $4.50 in the report published on August 28th of the previous year.
XERS Trading at 10.35% from the 50-Day Moving Average
After a stumble in the market that brought XERS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -16.23% of loss for the given period.
Volatility was left at 6.86%, however, over the last 30 days, the volatility rate increased by 5.75%, as shares surge +12.01% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +28.31% upper at present.
During the last 5 trading sessions, XERS rose by +8.26%, which changed the moving average for the period of 200-days by +97.96% in comparison to the 20-day moving average, which settled at $4.33. In addition, Xeris Biopharma Holdings Inc saw 50.00% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at XERS starting from Hecht Beth, who sale 40,000 shares at the price of $5.43 back on Mar 20 ’25. After this action, Hecht Beth now owns 1,353,510 shares of Xeris Biopharma Holdings Inc, valued at $217,244 using the latest closing price.
Hecht Beth, the Officer of Xeris Biopharma Holdings Inc, proposed sale 40,000 shares at $5.14 during a trade that took place back on Mar 20 ’25, which means that Hecht Beth is holding shares at $205,600 based on the most recent closing price.
Stock Fundamentals for XERS
Current profitability levels for the company are sitting at:
- -0.17 for the present operating margin
- 0.79 for the gross margin
The net margin for Xeris Biopharma Holdings Inc stands at -0.27. The total capital return value is set at -0.15. Equity return is now at value -617.16, with -16.37 for asset returns.
Based on Xeris Biopharma Holdings Inc (XERS), the company’s capital structure generated 1.12 points at debt to capital in total, while cash flow to debt ratio is standing at -0.14. The debt to equity ratio resting at -9.17. The interest coverage ratio of the stock is -1.1.
Currently, EBITDA for the company is -11.3 million with net debt to EBITDA at -14.28. When we switch over and look at the enterprise to sales, we see a ratio of 4.75. The receivables turnover for the company is 5.02for trailing twelve months and the total asset turnover is 0.63. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.67.
Conclusion
To put it simply, Xeris Biopharma Holdings Inc (XERS) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
